Drug Guides
In-depth guides to every GLP-1 medication — costs, side effects, dosing schedules, and where to buy.
Semaglutide
Ozempic • Wegovy • Rybelsus
Semaglutide is a GLP-1 receptor agonist approved by the FDA for both type 2 diabetes management and chronic weight management. It has become one of the most prescribed medications in the United States, with clinical trials demonstrating weight loss of up to 15% of body weight.
Read guide →
Tirzepatide
Mounjaro • Zepbound
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist that activates two incretin hormone pathways simultaneously. It is FDA-approved for type 2 diabetes as Mounjaro and for chronic weight management as Zepbound, and has demonstrated superior weight loss outcomes compared to semaglutide in head-to-head trials.
Read guide →
Wegovy
Wegovy
Wegovy is the brand-name formulation of semaglutide 2.4mg, specifically FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. It is a weekly subcutaneous injection developed by Novo Nordisk.
Read guide →
Ozempic
Ozempic
Ozempic is the brand-name formulation of semaglutide FDA-approved for type 2 diabetes management, though it has become widely prescribed off-label for weight loss. It is available in doses of 0.5mg, 1mg, and 2mg weekly, and is manufactured by Novo Nordisk. Ozempic also carries an FDA indication to reduce cardiovascular risk in adults with type 2 diabetes and heart disease.
Read guide →
Mounjaro
Mounjaro
Mounjaro is the brand-name formulation of tirzepatide FDA-approved for type 2 diabetes, manufactured by Eli Lilly. It is prescribed weekly by injection and has become extremely popular off-label for weight loss given its superior efficacy data. Like Ozempic, Mounjaro is often prescribed for weight management while awaiting broader obesity indications.
Read guide →
Zepbound
Zepbound
Zepbound is the brand-name formulation of tirzepatide 2.5–15mg specifically FDA-approved for chronic weight management, launched by Eli Lilly in late 2023. It is chemically identical to Mounjaro but approved specifically for obesity treatment, making it eligible for different insurance coverage pathways and savings programs.
Read guide →
Foundayo
Foundayo
Foundayo (orforglipron) is the first FDA-approved once-daily oral small-molecule GLP-1 receptor agonist for chronic weight management. Approved by the FDA on April 1, 2026, Foundayo is taken as a single tablet once a day with no food or water restrictions, marking a major change from injectable GLP-1s and from oral semaglutide (Rybelsus), which has strict food and water rules. In the 72-week ATTAIN-1 phase 3 trial, the highest dose produced 12.4% mean weight loss versus 0.9% on placebo.
Read guide →
Editorial guides
Each drug-specific page above covers FDA-label specifics and pricing. The editorial guides below add cross-drug context: which injection to choose, what insurance will pay for, and how the per-state Medicaid coverage decisions break down.
Sources & methodology — as of May 2026
- 1.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 2.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 3.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 4.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 5.FDA — Rybelsus (oral semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.